The SiroSkin study: A multi-centre randomised double-blind placebo-controlled trial of 1% topical sirolimus in the chemoprevention of facial squamous cell carcinomas in solid organ... (Stream 7) (2022–2027)
Grant type:
NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need